Development and preliminary clinical characterization of an MDT-defined surgical-window framework for complex pancreatic cancer: a retrospective cohort study.
- 1Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
- 2Peking University Research Center for Diagnosis & Treatment of Liver Cancer, Beijing, China.
Abstract
Patients with complex pancreatic cancer, including those with challenging local vascular anatomy, liver oligometastases, obstructive jaundice, gastrointestinal bleeding, or severe pain, often fall into a guideline grey zone not fully addressed by conventional stage- or resectability-based algorithms. We characterized how a multidisciplinary team (MDT)-guided surgical-window framework was implemented and the downstream clinical course following the resulting treatment decisions. We retrospectively reviewed 37 patients with complex pancreatic cancer discussed by the MDT at a tertiary academic center (Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China) between November 2017 and November 2020 and followed through November 30, 2022. Patients were characterized according to the realized MDT-guided pathway: a surgery-inclusive surgical-window pathway (n=20) or a non-surgical-window pathway (n=17). The analysis focused on pathway realization, disease-control patterns, functional and symptom status, and exploratory descriptive overall survival (OS), with progression-free survival (PFS) retained as a secondary descriptive time-to-event outcome. Because pathway assignment was clinically selected and incorporated evolving post-baseline information, clinical outcomes were summarized descriptively without formal between-pathway hypothesis testing. Nine of 37 index MDT decisions (24.3%) involved a surgery-inclusive strategy outside standard guideline-supported surgical indications, all in highly selected patients with stage IV low-burden metastatic disease. Functional status was summarized both as composite survival-functional states and among survivors at each assessment time point, with all between-pathway differences interpreted descriptively. In this single-center retrospective cohort, the MDT-defined surgical-window framework provided a structured way to integrate anatomy, metastatic burden, symptoms, treatment tolerance, and feasibility of subsequent care into individualized treatment decisions. The observed downstream disease-control, functional, symptom, and survival patterns are hypothesis-generating and do not establish a causal benefit of surgery or of MDT itself. Prospective studies with baseline-defined decisions are needed to validate the clinical usefulness of this framework.
Related
- Development and validation of machine learning models for predicting pancreatic injury observed after tigecycline initiation: a retrospective real-world study
- Immune–metabolic heterogeneity and prognostic associations in breast cancer: development of an eight-gene risk model and preliminary functional characterization of NAT2
- Clinicogenomic characterization and targeted therapy efficacy in Chinese patients with NTRK fusion-positive thyroid cancer: a preliminary retrospective cohort study.
- A call for lifelong learning: development and preliminary pilot testing of a discipline-specific performance appraisal framework for general dentists in Dubai.
- From silos to systems: a retrospective application of the measurement for change (M4C) framework to Grenada's intersectoral early childhood development strategy
BibTeX
@article{li2026development,
title = {{Development and preliminary clinical characterization of an MDT-defined surgical-window framework for complex pancreatic cancer: a retrospective cohort study.}},
author = {Xingfei Li and Delin Ma and Tantu Ma and Shuqing Wu and Jiye Zhu and Tao Li and Jie Gao},
journal = {Journal of gastrointestinal oncology},
year = {2026},
month = sep,
doi = {10.21037/jgo-2026-0759},
url = {https://europepmc.org/article/MED/42996876},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Development and preliminary clinical characterization of an MDT-defined surgical-window framework for complex pancreatic cancer: a retrospective cohort study.
AU - Xingfei Li
AU - Delin Ma
AU - Tantu Ma
AU - Shuqing Wu
AU - Jiye Zhu
AU - Tao Li
AU - Jie Gao
PY - 2026
DA - 2026/09/29
JO - Journal of gastrointestinal oncology
DO - 10.21037/jgo-2026-0759
UR - https://europepmc.org/article/MED/42996876
AB - Patients with complex pancreatic cancer, including those with challenging local vascular anatomy, liver oligometastases, obstructive jaundice, gastrointestinal bleeding, or severe pain, often fall into a guideline grey zone not fully addressed by conventional stage- or resectability-based algorithms. We characterized how a multidisciplinary team (MDT)-guided surgical-window framework was implemented and the downstream clinical course following the resulting treatment decisions. We retrospectively reviewed 37 patients with complex pancreatic cancer discussed by the MDT at a tertiary academic center (Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China) between November 2017 and November 2020 and followed through November 30, 2022. Patients were characterized according to the realized MDT-guided pathway: a surgery-inclusive surgical-window pathway (n=20) or a non-surgical-window pathway (n=17). The analysis focused on pathway realization, disease-control patterns, functional and symptom status, and exploratory descriptive overall survival (OS), with progression-free survival (PFS) retained as a secondary descriptive time-to-event outcome. Because pathway assignment was clinically selected and incorporated evolving post-baseline information, clinical outcomes were summarized descriptively without formal between-pathway hypothesis testing. Nine of 37 index MDT decisions (24.3%) involved a surgery-inclusive strategy outside standard guideline-supported surgical indications, all in highly selected patients with stage IV low-burden metastatic disease. Functional status was summarized both as composite survival-functional states and among survivors at each assessment time point, with all between-pathway differences interpreted descriptively. In this single-center retrospective cohort, the MDT-defined surgical-window framework provided a structured way to integrate anatomy, metastatic burden, symptoms, treatment tolerance, and feasibility of subsequent care into individualized treatment decisions. The observed downstream disease-control, functional, symptom, and survival patterns are hypothesis-generating and do not establish a causal benefit of surgery or of MDT itself. Prospective studies with baseline-defined decisions are needed to validate the clinical usefulness of this framework.
SN - 2078-6891
SN - 2219-679X
ER -